The FDA granted accelerated approval to the combination of pembrolizumab (Keytruda, Merck) plus lenvatinib (Lenvima, Eisai) for the treatment of patients who have advanced endometrial carcinoma that is not microsatellite instability–high (MSI-H) or mismatch repair–deficient (dMMR) and who have disease progression after systemic therapy but are not candidates for curative surgery or radiation.
This approval was granted under Project Orbis, an FDA initiative that provides a framework